Medical Xpress October 31, 2025
Luca Maini, assistant professor of health care policy in the Blavatnik Institute at Harvard Medical School, studies competition and regulation in pharmaceutical markets.
He has studied how national price negotiations in Europe affect access to new drugs and analyzed how mergers and acquisitions, different price negotiation methods, and government regulations influence spending and access to medicines in the United States.
Harvard Medicine News spoke with Maini to understand the stakes and the many factors at play with talk of tariffs on pharmaceuticals, direct-to-consumer sales of prescription medications, and the U.S. federal administration’s negotiations with pharmaceutical manufacturers.
Why study pharmaceutical markets?
Worldwide pharmaceutical markets were valued at more than $1.5 trillion in 2024. Some predictions say that number could reach $3...
Today's Sponsors
Today's Sponsor